Page last updated: 2024-08-25

bexarotene and Adenomatous Polyposis Coli

bexarotene has been researched along with Adenomatous Polyposis Coli in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Bommi, PV; Borras, E; Bowen, CM; Chang, K; Lynch, PM; Ozcan, Z; Reyes-Uribe, L; Scheet, PA; Sinha, KM; Taggart, MW; Thirumurthi, S; Vilar, E; Walter, L; Wu, W1
Choi, CI; Janakiram, NB; Mohammed, A; Qian, L; Rao, CV; Steele, VE1
Henney, JE1

Other Studies

3 other study(ies) available for bexarotene and Adenomatous Polyposis Coli

ArticleYear
Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
    Cancer prevention research (Philadelphia, Pa.), 2021, Volume: 14, Issue:9

    Topics: Adenomatous Polyposis Coli; Adenomatous Polyps; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinogenesis; Case-Control Studies; Cells, Cultured; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Intestinal Neoplasms; Male; Mice; Mice, Transgenic; Sulindac

2021
Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.
    Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:2

    Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anticarcinogenic Agents; Bexarotene; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin D1; Cyclooxygenase 2; Cytokines; Drug Screening Assays, Antitumor; Female; Intestinal Mucosa; Intestinal Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Oleic Acid; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Triglycerides

2012
From the Food and Drug Administration.
    JAMA, 2000, Mar-01, Volume: 283, Issue:9

    Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Bexarotene; Celecoxib; Cisapride; Contraindications; Cyclooxygenase Inhibitors; Drug Labeling; Gastrointestinal Agents; Humans; Lymphoma, T-Cell, Cutaneous; Pyrazoles; Receptors, Retinoic Acid; Sulfonamides; Tetrahydronaphthalenes

2000